Microsoft Word - 2.7_ŠÕ‘°−TŠv_2_-“ì‰ÆŠp.doc
|
|
- なお なかじゅく
- 5 years ago
- Views:
Transcription
1 CTD 2.7 Page (1) GDDQ 1) GDDQ AGHD GH GDDQ GDDQ * GDDQ * ) GDDQ AGHD
2 CTD 2.7 Page GDDQ GDDQ *1 *1 *2 AO CO GH *2 AGHD *2 * * ± µg/l : AO µg/l : AO µg/l: CO µg/l : CO µg/l : AO µg/l : AO µg/l : CO µg/l : CO GDDQ < < *1 * ) (a) 1% %4.9% 3.8% 194
3 CTD 2.7 Page GDDQ 274 * % *2 Musculoskeletal and connective tissue disorders Arthralgia Myalgia Back pain Peripheral swelling Nervous system disorders Headache Paraesthesia Carpal tunnel syndrome Dizziness General disorders and administration site conditions Oedema peripheral Fatigue NOS Oedema NOS Influenza like illness Infections and infestations Influenza Gastrointestinal disorders Respiratory, thoracic and nediastinal disorders Nasopharyngitis Skin and subcutaneous tissue disorders Sweating increased Investigations Vascular disorders NOS Hypertension NOS Metabolism and nutrition disorders * *2 MedDRA(J) 5.1 SOC, PT %
4 CTD 2.7 Page GDDQ () 274 * % *2 Psychiatric disorders Depression Surgical and medical procedures Neoplasms benign, malignant and unspecified (inclcysts and polyps) Cardiac disorders Eye disorders Reproductive system and breast disorders Injury, poisoning and procedural complications Ear and labyrinth disorder Endocrine disorders Renal and urinary disorders * *2 MedDRA(J) 5.1 SOC, PT % (b) GDDQ
5 CTD 2.7 Page GDDQ IU/ IU/ IU/ IU/ IU/ *1 *2 *1 20 mg 250 mg THYREX 0.1 mg CENTYL-KCL ELTROXIN OSTRADIOL MINIRIN SEMPREX HEXAHYDROBENZOATE 250 ADALAT OROS BURINEX CACIT SINTROM ZOCOR BURINEX MIXTARD 30/70 * 1 MedDRA(J) 5.1 PT *
6 CTD 2.7 Page GDDQ () *1 *2 * IU/ LASCAL THYRAX ADALAT OROS CAPOTEN THYRAX ASCAL TEMA ZAPAN FEROFUMMATE TRYPTISOL 2 2 IU/ IU/ IU/ 7 1 IU/ * 1 MedDRA(J) 5.1 PT * DIDROVIT DYTAC 50 mg 40 mg IMPORTAL10 g 250 mg LEVAXIN MINIRIN LEVAXIN MINIRIN
7 CTD 2.7 Page GDDQ () IU/ IU/ *1 *2 *1 LEVAXIN TROMBYL LEVAXIN MINIRIN T IU/ 50 mg IU/ 8 1 IU/ IU/ 5 mg T LEVAXIN 0.5 mg T MINIRIN 0.1 mg T 5 mg LEVAXIN NITROMEX SELOKEN ZOC TROMBYL FURIX MINDIAB T MINDIAB 5 mg 0.5 mg INSULATARD 100 U/mL 6 1 IU/ 1418 * 1 MedDRA(J) 5.1 PT *
8 CTD 2.7 Page GDDQ () IU/ IU/ IU/ 498 *1 *2 *1 ANUSOL CREAM C GTN SPRAY IU/ IU/ *1 MedDRA(J) 5.1 PT *2 2002
9 CTD 2.7 Page 201 (c) d 144 GDDQ *1 N=1715 N=1307 N=408 % % % * NOS Pituitary tumour NOS Transient ischaemic attack Craniopharyngioma Angina pectoris Cardiac failure NOS Pneumonia NOS NOS Cerebrovascular accident NOS NOS Pituitary tumour benign NOS Pituitary tumour removal NOS Vomiting NOS Chest pain NOS Neoplasm NOS NOS Headache NOS Cerebral infarction NOS Hemianopia NOS NOS Gastroenteritis NOS NOS Death NOS * *2 MedDRA(J) 5.1 PT 201
10 CTD 2.7 Page GDDQ Appendicitis Ovarian cyst Adrenocortical insufficiency acute *1 N=1715 N=1307 N=408 % % % * *2 MedDRA(J) 5.1 PT (d) GH C6 mg C12 mg % GH GH IGF-I IGFBP-3 IGF-I GH AGHD AGHD
11 CTD 2.7 Page GDDQ 274 * % *2 % NOS Pituitary tumour NOS NOS Neoplasm NOS Craniopharyngioma NOS Pituitary tumour benign NOS NOS Prostate cancer NOS Basal cell carcinoma Skin papilloma NOS Carcinoma NOS NOS Breast cancer NOS NOS Cyst NOS NOS Skin carcinoma NOS NOS Skin neoplasm NOS NOS Adenoma benign NOS Bronchial carcinoma NOS Colon cancer NOS 0 Colon carcinoma stage 0 Colon adenoma NOS Thyroid adenoma NOS NOS Lipoma NOS NOS Gastrointestinal neoplasm NOS Glioma * *2 MedDRA J 5.1 PT 203
12 CTD 2.7 Page GDDQ 274 * % *2 % Polycythaemia vera Astrocytoma Fibromatosis NOS Adenocarcinoma NOS Fibroadenoma of breast Papillary thyroid cancer Lipoma of breast NOS Breast neoplasm NOS NOS Brain neoplasm NOS NOS Bladder cancer NOS NOS Non-Hodgkin s lymphoma NOS NOS Lymphoma NOS * *2 MedDRA(J) 5.1 PT 204
13 CTD 2.7 Page 205 4) (a) % 3%5.5%4.6% 4.1% 3.7%3.7%3.2%3.2% 5% 9.2%2.3% GDED T002 GH
14 CTD 2.7 Page GDDQ *1 N=2253 *2 Nervous system disorders 65 N=217 % N=2036 % Headache Transient ischaemic attack Paraesthesia Sciatica Cerebral infarction Dizziness Carpal tunnel syndrome Musculoskeletal and connective tissue disorders Arthralgia Back pain Myalgia Peripheral swelling General disorders and administration site conditions Oedema peripheral Fatigue NOS Oedema NOS Influenza like illness Infections and infestations Influenza NOS Pneumonia NOS NOS Urinary tract infection NOS NOS Infection NOS Respiratory, thoracic and nediastinal disorders Nasopharyngitis Hyperventilation Cardiac disorders Angina pectoris Atrial fibrillation NOS Cardiac failure NOS Myocardial infarction Investigations *1 MedDRA J 5.1 SOC, PT *
15 CTD 2.7 Page GDDQ *1 N=2253 *2 Gastrointestinal disorders 65 N=217 % N=2036 % Nausea Vascular disorders NOS Hypertension NOS Skin and subcutaneous tissue disorders Sweating increased NOS Rash NOS Neoplasms benign, malignant and unspecified (incl cysts and polyps) NOS Pituitary tumour NOS NOS Prostate cancer NOS Surgical and medical procedures NOS Operation NOS Matabolism and nutrition disorders NOS Diabetes mellitus NOS Injury, poisoning and procedural complications Renal and urinary disorders Eye disorders Ear and Labyrinth disorders Vertigo Reproductive system and breast disorders Blood and lymphatic system disorder NOS(Anaemia NOS Psychiatric disorders Depression Endocrine disorders *1 MedDRA J 5.1 SOC, PT *
16 CTD 2.7 Page 208 (2) MedDRA Version / / N=60600 / N=17667 / * *1 // 208
17 CTD 2.7 Page *1 - - *2 1 *4 NA * *3 1 3 NOS *4 NA *5 NOS NOS 1 *4 NA *5 NOS 1 4 NA *5 NOS 1 NA *5 NOS 2 *4 NOS NOS 3 *4 NA *5 1 3 NOS *4 NOS 11 *4 NA *5 NOS 1 NA *5 NOS *4 *1 MedDRA(J) ver.6.0 *2 *3 *4 / *5 NA:
18 CTD 2.7 Page *1 - * * *4 NA *5 1 *4 NA *5 1 *4 NA *5 NOS 0 *4 NA * NA* *4 NA * NA *5 1 1 *3 NOS NOS *4 NOS NOS NOS NOS NOS NOS *1 MedDRA(J) ver.6.0 *2 *3 *4 : / *5 NA:
19 CTD 2.7 Page *1 - *2 NOS NOS *4 NA *5 NOS GH *3 NA *4 1 NOS 1 NA *4-1 *3 NA * NOS 1 *3 NA *4 NOS *3 NA * NOS *3 NA *4 NOS 2 NA *4 NOS NA * NA *4 NOS *3 NA *4 1 NA *4 *1 MedDRA(J) ver.6.0 *2 *3 / *4 NA:
20 CTD 2.7 Page * *2 NOS 2 2 *3 NA * NOS NA *4 1 NOS 6 *3 NA *4 - NOS 1 3 *3 NA *4 3 2 NOS NOS NOS 1 *3 NA *4 NOS *3 NOS *3 NOS GH NOS 5 NOS 4 NOS 4 *3 NOS 1 6 *3 NA *4 1 1 *3 NOS *1 MedDRA(J) ver.6.0 *2 *3 / *4 NA:
21 CTD 2.7 Page *1 * NA *3 1 2 NA * NA *3 1 NA *3 NOS NOS NA *3 3 2 * / NOS NA *3 NOS 2 1 NA *3 *1 MedDRA(J) ver.6.0 *2 *3 NA: *4
22 CTD 2.7 Page *1 - *2 1 NA *3 1 2 NA *3 1 2 NA *3 1 NA *3 1 NA *3 2 NA *3 NOS 1 NA *3 1 NA * NA *3 2 NOS NOS 1 2 NA *3 1 2 NA * NA *3 1 1 NA *3 1 2 NA * NA * NA *3 1 *1 MedDRA(J) ver.6.0 *2 *3 NA:
23 CTD 2.7 Page *1 - *1 MedDRA(J) ver.6.0 *2 *3 NA: *2 4 1 NA * NOS NA *3 NOS 1 1 NA *3 NOS 1 2 NOS NA *3 1 1 NOS 5 2 NOS 2 2 NOS 5 1 2
24 CTD 2.7 Page *1 - *1 MedDRA(J) ver.6.0 *2 *3 NA: *2 NOS NOS NOS 4 2 NOS NOS 4 2 NOS NOS 5 1 NOS 3 1 NOS NOS 4 2 NOS NOS NOS 6 1 NOS 5 1 NOS 5 1 NOS NOS 5 NOS NOS 4 2 NOS 4 1 NOS NOS 4 1 NOS 4 1 NOS NA *3 NOS 5 2 NOS 6 2
25 CTD 2.7 Page *1 - *1 MedDRA(J) ver.6.0 *2 *2 NOS 5 1 NOS NOS NOS NOS 5 1 NOS 6 2 NOS 4 1 NOS 6 2 NOS NOS 6 2 NOS NOS NOS NOS NOS NOS 6 NOS
26 CTD 2.7 Page *1 - *2 NOS NOS NOS 6 NOS *3 NOS NOS 6 NOS 7 2 NOS 7 2 NOS 7 1 NOS NOS 7 2 NOS 7 2 NOS NOS NOS NOS NA *4 1 NOS 1 1 NA *1 MedDRA(J) ver.6.0 *2 *3 *4 NA:
27 CTD 2.7 Page *1 - *2 NOS 1 1 NOS NOS NOS / *1 MedDRA(J) ver.6.0 *2 *3 NA: NOS 1 NA * NA 1 1 NOS NOS 1 NA *3 NOS 1 NA *3 NOS 1 NOS 5 1
28 CTD 2.7 Page Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, Zapletalova J, et al. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: A 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab; 2003; 88: Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson BA, et al: Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996; 81: Ito H, Ohshima A, Ohto N, Ogasawara M, Tsuzuki M, Takao K, et al. Relation between body composition and age in healthy Japanese subjects. Eur J Clin Nutr; 2001:55: Vahl N, Juul A, Jorgensen JOL, Orskov H, Skakkebaek NE, Chiristiansen JS. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: A two-year placebo-controlled study. J Clin Endocrinol Metab 2000; 85: Rudling M, Parini P, Angelin B. Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans. Growth Hormone & IGF Research 1999; 9: Leonsson M, Oscarsson J, Bosaeus I, Lundgren BK, Johannsson G, Wiklund O, et al: Growth hormone (GH) therapy in GH-deficient adults influences the response to a dietary load of cholesterol and saturated fat in terms of cholesterol synthesis, but not serum low density lipoprotein cholesterol levels. J Clin Endocrinol Metab 1999; 84: De Boer H, Blok GJ, van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Rev 1995; 16: Florakis D, Hung V, Kaltsas G, Coyte D, Jenkins PJ, Chew SL, et al: Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: A two year study. Clin Endocrinol 2000; 53: Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: Jφrgensen JOL, Pedersen SA, Laurberg P, Weeke J, Skakkebaek NE, Chiristiansen JS. Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxine-substituted central hypothyroidism. J Clin Endocrinol Metab 1989; 69: Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, et al: Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas G, Wood DF, et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998;83: De Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, Van Der Veen E. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996;81: Span JPT, Pieters GFFM, Sweep CGJ, Hermus ARMM, Smals AGH. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: Role of sex hormone replacement. J Clin Endocrinol Metab 2000; 85: ,,,,,. IRMA IGF-I, IGF-II, IGFBP ; 44: Grφfte T, Wolthers T, Jensen SA, Moller N, Jorgensen JOL, Tygstrup N, et al. Effects of growth 220
29 CTD 2.7 Page 221 hormone and insulin-like growth factor-i singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats. Hepatology 1997; 25: Shim M, Cohen P. IGFs and human cancer: implications regarding the risk of growth hormone therapy. Horm Res 1999; 51: Porretti S, Giavoli C, Ronchi C, Lombardi G, Zaccaria M, Valle D, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T4 therapy become mandatory? J Clin Endocrinol Metab 2002; 87: Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: Aronow WS. The older man's heart and heart disease. Med Clin North Am 1999; 83: Khan AS, Sane DC, Wannenburg T, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovascular Res 2002; 54: Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency [invited report of a workshop]. J Clin Endocrinol Metab 1998; 83: Fernholm R, Bramnert M, Hagg E, Hilding A, Baylink DJ, Mohan S, et al. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000; 85: Toogood AA, Shalet SM. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study. J Clin Endocrinol Metab 1999; 84: Wiren L, Boguszewski CL, Johannsson G. Growth hormone (GH) replacement therapy in GH-deficient women during pregnancy. Clin Endocrinol 2002; 57: McMillan CV, Bradley C, Gibney J, Healy ML, Russell-Jones DL, Sonksen PH. Psychological effects of withdrawal of growth hormone therapy from adults with growth hormone deficiency. Clin Endocrinol 2003; 59: Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab. 2002; 87: Kohno H, Ueyama N, Honda S. Unfavourable impact of growth hormone (GH) discontinuation on body composition and cholesterol profiles after the completion of height growth in GH-deficient young adults. Diabetes Obes Metab. 1999; 1: Underwood LE, Attie KM, Baptista J, the Genentech collaborative study group. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003; 88: Hartman ML, Crowe BJ, Kleinberg DL, Chipman JJ, Melmed S. Prospective multicenter safety surveillance of GH replacement in 2033 GH-deficient adults. Proceeding of ENDO The Endocrine Society 83rd Annual Meeting; 2001 June 20-23; Denver, USA. Chevy Chase: The Endocrine Society; Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm & IGF Res 2000; 10:
5.3mg () 1 2SD 2 1.5SD 17 15 2 4 4 3 ( ) 瘙 3 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 4 24 p * p ** IGF-I (ng/ml) 77.12±60.19 238.97±143.60 161.85±113.30 [124.08, 199.63] (p
More informationMicrosoft Word _fiYŁt”‚Š¿‹êŠŠ-“ì‰ÆŠp.doc
1.12 医薬品部会 2006.2 1.12 Page 1 1.12 CTD 5 5.3.3 PK 5.3.3.3 PK 5.3.3.3-1 ( GDFR) Comparison of hgh Pharmacokinetics Following Intravenous and Subcutaneous Administration of Humatrope in Japanese and Caucasian
More information日本化学療法学会雑誌第61巻第4号
μ μ μ μ μ μ Key words I β μ Sex Age (years) Height (cm) Evaluation items Table1.Characteristics of patients 1. mg/kg/day (n14) 2.5 mg/kg/day (n9) 5. mg/kg/day (n9) Total (n32) male 12 8 7 27 female 2 1
More informationDatRetPrePTC_R1.4_J.doc
MedDRA Release 1.4 MedDRA 10.1 ICH MedDRA 2007 912 MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER Release 1.4 Based on MedDRA Version 10.1 ICH-Endorsed Guide for MedDRA Users on Data Output
More information日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
More informationbody size no effect mechanical stress GH-IGF1 system + no effect? collagen production of fibroblasts + receptor + + Ia, Ib, II aldosterone renin angiotensin system Mechanical and Endocrinological
More information日本化学療法学会雑誌第60巻第4号
Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Key words β Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae μ μ S. pneumoniae H. influenzae S. pneumoniae
More information1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
More information第4回企画展 わたしたちの脳
"The Wisdom of the Body" The Structure of Brain Peripheral Nervous System Localization of Brain Function Homeostasis The Brain Difference between Humans and Other Mammals The history of brain research
More information1 2 D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3 5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10%
More informationJSACHD_Vol4_No2_Dec2015.book
4 2 30 35 (2015 ) cyanotic congenital heart disease, compensated erythrocytosis, iron replacement therapy ( 1) Hb = 57.5 (0.444 x ) 1) 1 2 30 (2015 12 ) SpO2 < 75% 2 (Ht) 2) Ht 3) QOL 4) MCV MCH TIBC Ht
More informationCQ 1,.,,.,,...,,,,,,.,,,,,,,MAO 2., 24,. A
CQ 1,.,,.,,...,,,,,,.,,,,,,,MAO 2., 24,. A 15 180 306 7,000 1 3 mg 103 92 89.3 60 60 100 173 28 16.2 3.52.92.3 1.7 1.7 1.7 2 64 78 80 3 ST 4 5 32 6 18 65 CQ 1 307 1 7,000 2006 ; 94 11 : 2149-2168. 2 2010
More information1) Roth, J., Glick, S. M., Yalow, R. S. and Berson, S. A.: Hypoglycemia: A potent stimulus to secretion of growth hormone. Science, 140, 987-988, 1963. 2) Ogawa, N.: Routine Ultramicro-Measurement of Human
More information慢性膵炎
- - 121 , g CCK g g - kgkcal kgkcal - g,,, - G.I.Res ; 10 : - ; 13 : - ; 22 : - Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol ; 20 : - Pfutzer RH, Schneider
More information特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More informationFig. 1 A: Effects of intramuscular injection of glucagon on the blood glucose levels (changes from basal, ƒ BG) as compared with effects of scopolamin
Fig. 1 A: Effects of intramuscular injection of glucagon on the blood glucose levels (changes from basal, ƒ BG) as compared with effects of scopolamine butylbromide during upper gastrointestinal endoscopy.
More informationEndocrinological and statistical analysis of ovarian function in hysterectomized patients Masaya HAYAFUJI, Kazuaki KATAYAMA and Matsuto MOCHIZUKI Depa
Endocrinological and statistical analysis of ovarian function in hysterectomized patients Masaya HAYAFUJI, Kazuaki KATAYAMA and Matsuto MOCHIZUKI Department of Obstetrics and Gynecology, Kobe University
More informationCTD 2 2.5 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.5 Page 3 2.5...8 2.5.1...8 2.5.1.1...8 2.5.1.2...8 2.5.1.2.1 GH...8 2.5.1.2.2 AGHD...9 2.5.1.2.2.1...9 2.5.1.2.2.2...10 2.5.1.2.2.3
More informationKey words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.
More informationC/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
More information第61巻5・6号(12月号)/特集1頁目(本刷)
Special Issue 1Sudden cardiac death symposium in Tokushima Special Issue 2How to do for your health? Reviews Original Epidemiologic problems of sudden death of school children in Tokushima Prefecture
More information1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
More informationスライド 1
1 2006 msv 2 2011 3 CT 2011 10mSv 10 40mSv 4 2012 217mSv 5 (CT) 2012 50 60mSv 6 2012 510mSv BRCA25 310 10mSv3% BRCA60-280% 3 5m Sv 1m Sv 12% . http://www.rea.or.jp/ire/pdf/report4.pdf 1.10 20 SMR 1.00
More informationTreatment for Rheumatoid Arthritis in Elderly Patients to be Provided by Orthopedic Surgeons Satoshi ITO Division of Clinical Immunology, Advanced Bio
Treatment for Rheumatoid Arthritis in Elderly Patients to be Provided by Orthopedic Surgeons Satoshi ITO Division of Clinical Immunology, Advanced Biomedical Applications, Graduate School of Comprehensive
More informationMicrosoft Word - 「黄砂とその健康影響について」小冊子180323版
...1...1...1...2...4...4...4...6...7...7...7...7...8...8...9...9...10... 11... 11... 11... 11...12...12...13...16...18...20 1 1-1 1-2 1 1 km 24.5 m/s 10 50 m 1 1-3 μm 1-4 1-5 2 8 http://www.jma-net.go.jp/sat/himawari/obsimg/image_dust.html
More informationuntitled
21 1 26 1 US6759035University of Southern California 1. A method for decreasing graft rejection of a solid organ by a recipient comprising: a) isolating peripheral blood mononuclear cells (PBMC) from a
More informationE Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
More informationMedical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 10 (2012) Key words ö γ µ Graves disease and Hashimoto s thyroiditis are autoimmune thyroid diseases. Graves disease causes
More information2) Dolphin, A., Jenner, P., Marsden, C,D., Pycock, C. and Tarsy, D. : Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents, Psychopharmacologia, 41 : 133, 1975.
More information36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationuntitled
1 2 3 4 5 6 7 8 9 10 11 12 13 µ µ µ 14 15 16 17 1. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, Chiaramonte M: Development of type 1 diabetes mellitus during interferon alfa
More information小児感染免疫第23巻第1号
Vol. 23No. 163 42 HPV HPV 1113 HPV 42 HPV HPV HPV 1 1 510 1020 HPV 1020 510 HIV 0.1 0.005 HIV 2030 HIV 0.2 510 HPV 1020 15 HIV 2030 HIV HIV 0.2 0.1 Takeyuki Sato 2608677 181 64 2011 2 1 1518 6,000 513
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More information多目的な障害予防のための「ニコニコ体操」
"Enjoyable Exercises" as multipurpose prevention exercise Koji Yamashita1) Department of Physical Therapy, Faculty of Health Sciences, Aomori University of Health and Welfare 13)Marras WS, Ferguson
More information164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10
163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination
More information2009年133巻3号3月号.indb
Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More information21-07_後藤論文.smd
2015; 21: 5866 Yoichi Goto: Current status and future perspective of cardiac rehabilitation in Japan. J Jpn Coron Assoc 2015; 21: 5866 I 1 1 3 1 2 3 QOL 2 Fig. 1 1 196070 AMI AMI 1980 AMI CABG comprehensive
More informationuntitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
More informationsick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
More informationKey words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
More informationCA CA19-9 CA19-9 CA CA CA19-9 ARCHITECT i 2000SR CLIA U/mL CA % CA CA
原 著 30 22-29, 2015 CA19-9 CA19-9 CA19-9 2006 12013 6 CA19-9 32,508 37.0U/mL 790 2 CA19-9 320 CA19-9 ARCHITECT i 2000SRCLIA 0.0 37.0U/mL 8 4 1 2 18CA19-9 198.2 46.4 2,968 U/mL 5 3 2.5% CA19-9 2.5% CA19-9
More informationFig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad
Key words: Female with bladder irritability, Subjective symptoms, Pyuria, Bacteriuria Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution
More information2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
More information1) Zapf J, Walter H and Froesch ER: Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.
More information11) Kumar, R., et al.: Lancet, 1 : 90, 1973. 12) Baek, S. M., et al.: Ann. Surg., 177: 253, 1973. 13) Beak, S. M., et al.: Ann. Surg., 178 : 605, 1978. 14) Beak, S. M., et al.: Surgery, 77: 632, 1975.
More information老人性不整脈
資料 : QOL CHADS NOAC はじめに common disease 高齢者の不整脈の頻度, AF AVB RBBB LBBB Cardiovascular Health Study, 137 表 1 Outpatient Atarashi Cardiovascular Health Study Monolio No F M Ectopic beats Supraventricular.
More informationInfluences of mortality from main causes of death on life expectancy. \ An observation for the past 25 years, 1950-1975, in Japan \ Takao SHIGEMATSU* and Zenji NANJO** With the Keyfitz-Nanjo method an
More information3) Beresford SAA, Weiss NS, Voigt LF, et al: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458-461, 1997 4) Daly
More informationCHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
More information; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
More informationMicrosoft Word - 01_2_【資料1】ICD最近の動向(脳卒中、認知症)170626(反映)
ICD-11 における議論の最近の動向 1. 脳血管疾患 ICD-10 で循環器系の疾患の章に分類されていた脳血管疾患 ( くも膜下出血 脳内出血 脳梗塞 脳卒中等 I60-I69) が 神経系の疾患の章に移動 2016 年 10 月 3 日版 2017 年 4 月 2 日版 第 11 章循環器系の疾患 第 8 章神経系の疾患 脳血管疾患 ( 詳細 ) 1 2. 認知症 ICD-10 では 認知症
More informationUnderstanding Stem Cell Transplant 2007
Understanding Stem Cell Transplant IMF International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
More informationA study on thyroid function in patients on chronic dialysis Masahumi Kikkawa, Issei Tanaka, Naoki Haruta, Takao Hinoi, Tamaki Nakatani, Kazuaki Miyamo
A study on thyroid function in patients on chronic dialysis Masahumi Kikkawa, Issei Tanaka, Naoki Haruta, Takao Hinoi, Tamaki Nakatani, Kazuaki Miyamoto Artifical Kidney Center, Hiroshima Prefectural Hiroshima
More information研究成果報告書
系 レニン 1. Ito D, Ito O, Mori N, Suda C, Hao K, Cao P, Muroya Y, Takashima K, Shimokawa H, Kohzuki M. Exercise training upregulates nitric oxide synthases in the kidney of rats with chronic heart failure.
More information1) Steinbrocker, O.: The shoulder-hand syndrome in reflex dystrophy of the upper ex- tremity, Ann. Intern. Med., 29: 22, 1948. 5) Greenfield, A. D. M., Whitney, R. J. and Mowbray, J. F.: Methods for the
More information橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
More information2
2 3 4 5 6 7 8 9 1 2 3 4 5 10 11 12 1 2 1 2 1 2 13 14 3 17 15 1 2 3 D Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression level in non-small cell lung cancer a preliminary
More informationTable 1 Comparsion of background of the 86 patients with colorectal perforation All Survival Death p-value No. of patients 86 (100%) 74 (86%) 12 (14%)
Japanese Journal of Acute Care Surgery 2013; 3: 55~60 原著 非外傷性大腸穿孔 86 症例の臨床的検討 上田健太郎岩﨑安博山添真志川副友川嶋秀治國立晃成酒谷佳世山上裕機加藤正哉 x 所属 : 和歌山県立医科大学救急集中治療医学講座住所 : 641-8510 和歌山県和歌山市紀三井寺 811-1 Table 1 Comparsion of background
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More information繝励Μ繝ウ繝
257 2013.4 2014.3 other iatrogenic immunodeficiency associated lymphoproliferative disorders 1 pp.149 154 2013. 6 16 1 pp.367 371 2014. 3 The effects of sports drink osmolality on fluid intake and immunoendocrine
More information1) Delbet P: Retrocissement du choledoque. Cholecysto-duodenostomie. Bull Mem Soc Nat Chir 50: 1144-1146, 1924 2) Wiesner RH, LaRusso NF: Clinicopathologic Features of the Syndrome of Primary Sclerosing
More information2012 Vol. 23 No pseudothrombophlebitis pseudothrombophlebitis
pseudothrombophlebitis 5 424 163 38.1 26 6.1 5 1.2 230 2 3 66.4 51 80 2 3 2 2 1 2012 23 3 261-265 pseudothrombophlebitis 1 2011 7 11 30 2010 2 5 47 Fig. 1 Ultrasonography showed a low echoic cyst in the
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationSTUDIES ON THE RELATION BETWEEN LATE DUMPING SYNDROME AND GLUCAGON RESPONCES TO GLUCOSE Taisuke MATSUI The First Department of Surgery, Nara Medical U
STUDIES ON THE RELATION BETWEEN LATE DUMPING SYNDROME AND GLUCAGON RESPONCES TO GLUCOSE Taisuke MATSUI The First Department of Surgery, Nara Medical University, Kashihara (Director: Prof. H. Nakano) This
More informationResponse of pre-and postoperative Glucose- Insulin-Kalium (GIK) loading in patients with valve replacement. Isao Sakashita*, Takeshi Ando*, Tetsunosuk
Response of pre-and postoperative Glucose- Insulin-Kalium (GIK) loading in patients with valve replacement. Isao Sakashita*, Takeshi Ando*, Tetsunosuke Matsukawa* *Department and Ken-ichi Asano*. of Thoracic
More informationuntitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
More informationHEART'S Original A case of Brugada syndrome with a high defibrillation threshold in which defibrillation was successful by Active Can off defibrillation Keisuke Kawachi, Yukei Higashi, Yuuki Honda, Kouhei
More information第79回_プログラム.indd
Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial
More informationuntitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
More information日本化学療法学会雑誌第51巻第2号
piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC
More informationJIPAD2015.pptx
ICU 機能評価委員会報告 JIPAD update 2015 - 過去 現在 そして未来へ - 内野滋彦 東京慈恵会医科大学附属病院集中治療部 x 日本集中治療医学会学術集会 COI 開示 筆頭発表者 : 内野滋彦 1 役員 顧問職等の報酬 * 無 2 株式の利益 * ( または株式の5% 以上 ) 無 3 特許権使用料など * 無 4 講演料など * 無 5 原稿料など * 無 6 研究費 助成金など
More informationmg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD
31 1 15 20 2016 15 3 65 5 mg 8 mg 10 15 201X 7 1 11 15 Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD AKI HD 2004 48 Acute Kidney Injury AKI 48 Cr 0.3 mg/dl
More informationuntitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- twatanab@oncoloplan.com http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
More information988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More informationindd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
More information1) Katsuki S: Epidemiological and clinicopathological study on cerebrovascular Japan. Prog Brain Res 21B: 64-89, disease in 1966. 2) Omae T, Ueda K: Risk-factors of cerebral stroke in Japan: Prospective
More informationuntitled
CONTENTS 01 02-03 04-05 06-07 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 48-49 50-51 52 01 02 Mishima,Michiaki 03 04 05 06 07 09 10 11
More informationorororor oror CINAHL breast cancerhormonal therapyorendocrine therapyortamoxifenorgoserelinside effectorsymptomexperien
72017 3 資料 内分泌療法を受けている乳がん患者の苦痛体験に関する文献検討 A Literature Review regarding Distress Experienced by Breast Cancer Patients Undergoing Endocrine Therapy 四方文子 1), 鈴木久美 2) Ayako Shikata 1),Kumi Suzuki 2) キーワード
More informationuntitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
More informationCHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
More informationuntitled
1) American College of Surgeons:Advanced Trauma Life Support Course Manual. American College of Surgeons 1997;103-112 24 2) American Society of Anesthesiologists Task Force:Practice guideline for blood
More information日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
More informationSBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
More information3) Stedmann, E. et al.: Biochem. J., 29; 2107, 1935. 4) Reiss, M.. Hemphill, R. E. E ENature, 161 ; 18, 1948. 5) Tower, D. B. & D. MeEachern: Canada J. Reserch., 27; 105, 120, 132, 1949. 6) Wolleman, M.
More information本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
More information胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic
More informationTherapy for Asthenopia in Cases of Convergence Insufficiency Hiroko TAKASAKI, C.O.J., Nobuko INAGAMI, C.O.J., and Kayoko TAKENAWA, C.O.J.. Orthoptic c
Therapy for Asthenopia in Cases of Convergence Insufficiency Hiroko TAKASAKI, C.O.J., Nobuko INAGAMI, C.O.J., and Kayoko TAKENAWA, C.O.J.. Orthoptic clinic, Department of Ophthalmology, (Director: Prof
More informationPowerPoint Presentation
Glioma 28% astrocytoma (WHO I) 0.28 anaplastic (WHO II/III) 0.18 Glioblastoma (WHO IV) 0.32 others 0.22 Meningioma partly malignant) 26% Pituitary adenoma 17% Neurinoma 11% Craniopharyngioma etc 5% Others
More information*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells
*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells Abbreviation: LC=large cleaved nuclei, LNC=large non-cleaved nuclei, IMBL=immunoblastic nuclei,
More informationClinical Characteristics in Multiple Endocrine Neoplasia Type 1 in Japan: A review of 106 patients Katsuhiko YOSHIMOTO 1,2, Shiro SAITO 1 1. The First Department of Internal Medicine 2. Otsuka Department
More information食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
More informationThe Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
More informationVOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
More information27 Hypothyroidism minimizes experimental autoimmune myocarditis in rats Zhi-ping Zong and Shinobu Matsui Medical Res. Inst., Kanazawa Medical University It has been well known that thyroid hormone is essential
More information_06.indd
30, 35-39, 2010 0.15% 1 C 40 20 1 cm 5 mm WBC 9,400, RBC 259 10 4, Hb 8.5 g/dl, Ht 25.5%, Plt 29 10 4, BUN 116 mg/dl, Cr 7.9 mg/dl, 125 mg/dl, HbA1c 4.3%, ft3 1.97 pg/ml, ft4 1.05 ng/dl, TSH 1.09 μiu/ml,
More informationWHO Library Cataloguing in Publication Data 2003, Wilkinson,Richard Marmot,Michael Social determinants of health SDH The social gradient Stress Early life Social exclusion Work Unemployment Social support
More information